- /
- Supported exchanges
- / XETRA
- / MRK.XETRA
Merck KGaA (MRK XETRA) stock market data APIs
Merck KGaA Financial Data Overview
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Merck KGaA (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Merck KGaA data using free add-ons & libraries
Get Merck KGaA Fundamental Data
Merck KGaA Fundamental data includes:
- Net Revenue: 21 271 M
- EBITDA: 5 771 M
- Earnings Per Share: 6
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: 2.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck KGaA News
New
Does Merck KGaA’s Biotech Expansion Signal Opportunity After 20% Share Price Drop in 2025?
Are you wondering if Merck KGaA is undervalued, overvalued, or finally priced just right? Let's demystify the numbers together and see if there's opportunity hiding beneath the surface. Despite its re...
High-Performance Supercomputer Launched to Advance AI Innovation and Scientific Discovery
Equinix and Lenovo to provide digital foundation for Merck KGaA, Darmstadt, Germany— from accelerating drug discovery to pioneering new materials for next-generation semiconductor chips REDWOOD CIT...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders
Partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars LEXINGTON, Mass., November 20, 2025--(BUSINESS WIRE)--Valo Health, Inc. ("Valo"), a company pioneer...
Merck KGaA (MKGAF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
This article first appeared on GuruFocus. Organic Revenue Growth: 5.2% increase across all sectors. EBITDA Pre: Increased by 8.8% organically to EUR1.69 billion. Net Sales: Increased by 1% to EUR5.31...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.